Evaluation of the Effectiveness of Liver Enzymes for Patients with Beta Thalassemia in Baghdad City Taking Iron Chelation Drugs Deferoxamine and Deferosirox

Hussein Ali  Kamel; Asma Hassan Juma  Al-Samarrai

doi:10.17605/cajmns.v4i1.1332

Hussein Ali Kamel Assistant professor, University of Samarra/College of Education/Department of Biology
Asma Hassan Juma Al-Samarrai University of Samarra/College of Education/Department of Biology

DOI: https://doi.org/10.17605/cajmns.v4i1.1332

Keywords: Deferoxamine, deferosirox, liver enzymes, beta thalassemia

Abstract

The study was conducted for the period from September 2022 to January 2023, and samples were collected in the city of Baghdad at the Genetic Blood Diseases Center of Ibn Al-Baladi Hospital for Children on the Rusafa side, the Hereditary Blood Diseases Center of Al-Karama Teaching Hospital on the Karkh side, and private clinics for hematologists in Baghdad. And blood samples were drawn from 70 patients with thalassemia major who were treated with regular blood transfusions and iron-chelating treatments Deferoxamine (DFO) and Deferasirox (DFX), where they were divided into two groups, each group 35 patients according to the type of treatment, and the control group (healthy) numbered 30 and in each group Three age groups, the first age group G1 / 5-10 years, the second age group G2 / 11-20 years, and the third age group G3 / 21-30 years All biochemical tests were performed, including liver enzymes [Alanine aminotransferase (ALT), Aspartate aminotransferase (AST)] and the concentration of iron and ferritin. The results of the current study are explained. There was a significant increase (P≤0.05) for liver enzymes in ALT and AST for the two groups of beta thalassemia patients, and the deferoxamine group was higher, which was taken subcutaneously. AST enzyme was elevated for all age groups in the DFO group, while ALT enzyme was elevated in the first age group compared to the same group

References

1. Al-Salhi, Haider Fadel Akab. (2018). Evaluation of the immune status and viral infections of thalassemia patients dependent on blood transfusions in Thi-Qar Governorate. Master Thesis. College of Science. Dhi Qar University.
2. Angastiniotis, S. Lobitz, (2019) Thalassemias: an overview, Int. J. Neonatal Screen. 5 (1) 16.
3. Asadov, Z. Alimirzoeva, T. Mammadova, G. Aliyeva, S. Gafarova, J. Mammadov, (2019) beta-Thalassemia intermedia: a comprehensive overview and novel approaches, Int. J. Hematol. 108 (1) 5–21.
4. Bonfils, L.; Ellervik, C.; Friedrich, N.; Linneberg, A. and Sandholt, (2015).C. H. Fasting serum levels of ferritin are associated with impaired beta cell function and decresed insulin sensitivity ; A population based study . Diabetologian,;58: 523 – 533
5. Crippa, Annamaria Aprile, Laura Silvestri, Silvia Rivis, Samantha Scaramuzza, Stefania Pirroni, Maria Antonietta Avanzini, Luca Basso-Ricci, Raisa Jofra Hernandez, Marco Zecca, Sarah Marktel, Fabio Ciceri, Alessandro Aiuti, Giuliana Ferrari, Maria Ester Bernardo, (2019) Bone marrow stromal cells from b-thalassemia patients have impaired hematopoietic supportive capacity, JCI 129 1566–1580.
6. Cullis, J. O., Fitzsimons, E. J., Griffiths, W. J., Tsochatzis, E., Thomas, D. W., and British Society for Haematology. (2018). Investigation and management of a raised serum ferritin. British journal of haematology, 181(3): 331-340.
7. Dreuzy, E.; Bhukhai, K.; Leboulch, P.; & Payen, E. (2016). Current and Future Alternative Therapies for Beta-thalassemia Major. Biomedical Journal, 39(1), 24–38.
8. Farashi, S.; & Harteveld, C. L. (2018). Blood Cells , Molecules and Diseases Molecular basis of α -thalassemia. Blood Cells, Molecules and Diseases, 70(10), 43–53.
9. Garcia, A. J., Okeagu, C. N., Kaye, A. D., and Abd-Elsayed, A. (2021). Metabolism, Pathophysiology, and Clinical Considerations of Iron Overload, a Comprehensive Review. Essentials of Blood Product Management in Anesthesia Practice, 289-299.
10. Ghazanfari, A., Jafarzadehpour, E., Heydarian, S., Dailami, K. N., and Karami, H. (2019). Comp rison of contr st sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox. Journal of optometry, 12(3):168-173.
11. Hashmi, H.; Muslahi, M.; Muslahi, H.; & Lamki, M. Al. (2008). Prevalence of Endocrinopathies in Patients with Beta-Thalassaemia Major - A Cross-Sectional Study in Oman. Iranian Academic Journal, 23(4), 257–262.
12. Jafar, N. A. (2018). The use of Interleukin -10 as a Biomarker for Diagnosis of Viral Hepatitis type C Infections and Related Liver Function in Beta- thalassemic Major Patients. Journal of Medent Alelem College, 10(1), 8–13.
13. Mohammadi, S.; & Khodabandehloo, M. (2017). Prevalence of Hepatitis C Virus Antibodies among Beta-Thalassemia Major Patients in Kurdistan Province , Iran. Iranian Academic Journal, 12(3), 23–31.
14. Mohammed, Z.; & Jeddoa, A. (2018). Molecular Characterization of Beta- thalassemia Mutations in Holy Karbala. Journal of Science College University of Kerbala, 88(August), 12–19 Contemporary Medical Sciences, 2(5), pp. 15–19.
15. Rujito, L., Widodo, Y. R., Sakina, G., Santosa, Q., & Hapsari, A. T. (2020). Glutathione S transferase and catalase gene polymorphisms did not tend to influence the severity of hemoglobin E/β-thalassemia. Universa Medicina, 39(1): 19-26.
16. Suman, R. L.; Sanadhya, A.; Meena, P.; & Goyal, S. (2016). Correlation of liver enzymes with serum ferritin levels in β -thalassemia major. International Journal of Research in Medical Sciences, 4(8), 3271– 3274.
17. Taher, K.M. Musallam, M.D. (2021) Cappellini, beta-Thalassemias, N. Engl. J. Med. 384 (8) 727–743.
18. Waseem, F.; Khemomal K. A. and Sajid.( 2011).R. Antioxidant status in beta – thalassemia major: A Single – center study. Indian Journal of pathology and Microbiology.;54 (4): 761 – 763.